FDA Approves RASONQUE and WELTRUZA, Boosting Royalty Pharma Outlook
What happened
The FDA granted approvals for RASONQUE and WELTRUZA on November 4, 2026. Royalty Pharma management highlighted these approvals as part of the company's commercial and pipeline opportunities. Separately, Royalty Pharma reported quarterly revenue of $690.10 million, missing analyst estimates of $884.84 million.
From themarketsdaily.com
Why it matters
The regulatory approvals are a key driver of Royalty Pharma's portfolio value. Following the approvals, the company raised its 2026 guidance for the third consecutive quarter, now expecting portfolio receipts of $3.5 billion–$3.55 billion.
From themarketsdaily.com
Who's involved
- FDARegulatory agency that granted approvals for RASONQUE and WELTRUZA
- Royalty PharmaBiopharmaceutical company whose portfolio value is driven by FDA approvals
- Pablo LegorretaFounder and CEO of Royalty Pharma
- Morgan StanleyU.S. investment bank that actively covers and rates Royalty Pharma
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- Royalty PharmaSpeculative
Royalty Pharma could see increased future royalty revenue due to the FDA approvals of RASONQUE and WELTRUZA.
- Bank of AmericaSpeculative
Bank of America might upgrade its investment rating or coverage following the positive regulatory news for Royalty Pharma.
Keep exploring
The entities involved
- FDA
-
Royalty Pharma
biopharmaceutical company based in New York City
Related events
- Generic medicine services are seeking approval for launch from the FDA.
- ADC Therapeutics received accelerated approval for its drug from the FDA.
- Takeda is seeking FDA approval for its drug ORZEYFUL.
- Discussion on the limits of pharmacotherapy and the role of FDA approvals.
- A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.